Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IFRX with free AI briefings, catalyst countdowns, and dilution alerts.

IFRX · InflaRx N.V.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$115.4M Cash on Hand
74.1mo Cash Runway
Follow IFRX by email Get an email when IFRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IFRX, unsubscribe in one click. Privacy

📣 What IFRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vilobelimab Pyoderma Gangrenosum Phase 3 · NCT05964413 Terminated
BSC Mouse Severe COVID-19 Pneumonia Phase 2/3 · NCT04333420 Completed
HS high dose treatment Chronic Urticaria, Idiopathic Phase 2 · NCT06555328 Terminated
HS medium dose treatment Chronic Urticaria, Idiopathic Phase 2 · NCT06555328 Terminated
Glucocorticoid Granulomatosis With Polyangiitis (GPA) Phase 2 · NCT03895801 Completed
CSU non responders IgE - high dose treatment Chronic Urticaria, Idiopathic Phase 2 · NCT06555328 Terminated
CSU lower dose treatment Chronic Urticaria, Idiopathic Phase 2 · NCT06555328 Terminated
CSU high dose treatment Chronic Urticaria, Idiopathic Phase 2 · NCT06555328 Terminated
Cohort C: bevacizumab Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06701656 Recruiting
Cohort B: paridiprubart Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06701669 Recruiting
Cohort A: vilobelimab Acute Respiratory Distress Syndrome (ARDS) Phase 2 · NCT06703073 Recruiting
CaCP29, a humanized monoclonal antibody Drug Safety Phase 1 · NCT01319903 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IFRX holds $115.4M in cash and short-term investments and burns about $4.7M/quarter from operations, an estimated runway of 74.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IFRX files for a raise →

👥 Who Owns IFRX

Insiders 6% Other 5%+ holders 30.4% Institutions 63.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
Montanova Capital, LLC Institution (13G, 5%+) 22,933,910 31.72% 2026-06-30
TCG Crossover GP III, LLC 5%+ holder (13G) 14,500,000 20.06% 2026-05-07
Commodore Capital LP Institution (13G, 5%+) 9,268,220 12.82% 2026-09-30
Sirenia Capital Management LP Institution (13G, 5%+) 8,911,348 12.33% 2026-06-30
FMR LLC Institution (13G, 5%+) 8,163,341 11.29% 2026-06-30
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 7,933,910 10.97% 2025-12-31
Dapice Joshua J. 5%+ holder (13G) 7,500,000 10.37% 2026-05-07
Renfeng Guo
Chief Scientific Officer, Director
Insider 1,762,144 2.44% 2026-03-18
Niels Riedemann
Chief Executive Officer, Director
Insider 1,068,908 1.48% 2026-03-18
Mark Kubler
Director
Insider 960,015 1.33% 2026-03-18
Nicolas Fulpius
Director
Insider 490,052 0.68% 2026-03-18
Richard Brudnick
Director
Insider 50,000 0.07% 2026-03-18

Share count 72,292,859 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IFRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IFRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.